Mirum to report Phase 3 EXPAND topline data for LIVMARLI in ultra-rare cholestatic liver diseases Oct. 12
MIRM•Mirum scheduled an investor call for Oct. 12, 2026, to present topline Phase 3 EXPAND results for LIVMARLI in ultra-rare cholestatic liver diseases. The data will cover cholestatic pruritus treatment in patients aged 6 months or older, including biliary atresia.
1. Investor call scheduled
Mirum scheduled an investor call for Oct. 12, 2026, to present topline Phase 3 EXPAND results for LIVMARLI in ultra-rare cholestatic liver diseases. The data will cover treatment of cholestatic pruritus in patients aged 6 months or older, including biliary atresia; results have not yet been presented.
